Evidence map›Paper›PMID 41806143›Full record

ArticleEndocrine pathology2026

In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome.

Francesca Cioppi, Tommaso Orioli, Giulia Cantini, Tonino Ercolino, Federica Cioppi, Guillaume Assié, Anne Jouinot, Anna Aurora Dedonno, Raffaella Santi, Ronald R de Krijger and 5 more

Abstract readCase Reports
In one paragraph

Article in Endocrine pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesca CioppiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, 50139, Italy.ORCID http://orcid.org/0000-0002-7718-6347
Tommaso OrioliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, 50139, Italy.
Giulia CantiniEuropean Network for the Study of Adrenal Tumors (ENSAT) Centre of Excellence, University of Florence, Florence, 50139, Italy.ORCID http://orcid.org/0000-0002-9159-9199
Tonino ErcolinoCentro di Ricerca & Innovazione Sulle Patologie Surrenaliche, AOU Careggi, Florence, 50134, Italy.
Federica CioppiAzienda Ospedaliero-Universitaria Careggi, (AOUC), Florence, 50139, Italy.
Guillaume AssiéUniversité Paris Cité, CNRS, INSERM, Institut Cochin, Paris, F-75014, France.ORCID http://orcid.org/0000-0001-9590-0906
Anne JouinotUniversité Paris Cité, CNRS, INSERM, Institut Cochin, Paris, F-75014, France.ORCID http://orcid.org/0000-0002-7922-2065
Anna Aurora DedonnoEuropean Network for the Study of Adrenal Tumors (ENSAT) Centre of Excellence, University of Florence, Florence, 50139, Italy.
Raffaella SantiDepartment of Health Sciences, University of Florence, Florence, 50139, Italy.ORCID http://orcid.org/0009-0005-5317-7533
Ronald R de KrijgerPrincess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-6871-1296
Mario MaggiEuropean Network for the Study of Adrenal Tumors (ENSAT) Centre of Excellence, University of Florence, Florence, 50139, Italy.ORCID http://orcid.org/0000-0003-3267-4221
Matteo BenelliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, 50139, Italy.ORCID http://orcid.org/0000-0003-1227-356X
Letizia CanuEuropean Network for the Study of Adrenal Tumors (ENSAT) Centre of Excellence, University of Florence, Florence, 50139, Italy.ORCID http://orcid.org/0000-0003-4995-8108
Gabriella Nesi *European Network for the Study of Adrenal Tumors (ENSAT) Centre of Excellence, University of Florence, Florence, 50139, Italy. gabriella.nesi@unifi.it.ORCID http://orcid.org/0000-0002-2614-944X
Michaela Luconi *European Network for the Study of Adrenal Tumors (ENSAT) Centre of Excellence, University of Florence, Florence, 50139, Italy. michaela.luconi@unifi.it.ORCID http://orcid.org/0000-0001-5186-064X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenal lesions often occur in patients with multiple endocrine neoplasia type 1 (MEN1), mostly adrenal cortical adenomas (ACAs), although the frequency of adrenal cortical carcinomas (ACCs) is higher than in the general population. The coexistence of benign and malignant masses has seldom been documented, leaving open the question of ACC progression from benign forms. We report a comprehensive genetic characterization of three adrenal cortical tumor samples obtained from a familial MEN1 patient, operated for the rapid progression of an initially stable nonfunctional adrenal incidentaloma. Histologically, the tumor consisted of a small ACA contiguous to a large ACC, which subsequently relapsed. Exome sequencing of ACC, ACA and recurrence evidenced a MEN1 loss of heterozygosity (LOH) in ACC but not in ACA, where, however, a second hit driven by alternative mechanisms could not be excluded. The majority of the ACA variants were found to co-occurred in ACC (n = 36/42) and were benign, except for two of unknown significance in KANK1 and REN genes, described as associated with renal cancer. Among variants shared between ACC and its recurrence (n = 69), 11 were Tier III, while 2 affecting TP53 and NF1 genes were pathogenic. Bioinformatic clonal evolution analysis identified one clone - characterized by TP53 and NF1 mutations - absent in ACA but present in ACC and recurrence, as well as 2 clones shared between ACA and ACC but lost in the recurrence. In conclusion, comparative Whole Exome Sequencing (WES) analysis of three adrenal tumors in a MEN1 patient suggests a possible relationship between malignant and benign lesions occurring in MEN1 patients, without, however, demonstrating any causal adenoma-to-carcinoma progression driven by MEN1 LOH. Overall, these data further suggest an increased risk of MEN1 patients to develop adrenocortical malignancy.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical AdenomaAdrenocortical CarcinomaMultiple Endocrine Neoplasia Type 1AdultFemaleHumansLoss of HeterozygosityMiddle AgedACC and ACAClonal evolutionMEN1Molecular profilingSomatic mutationsWhole Exome Sequencing

Identifiers

PMID41806143
PMCPMC12975836

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.